Disc Medicine, Inc. (NASDAQ:IRON) Holdings Trimmed by Eagle Asset Management Inc.

Eagle Asset Management Inc. cut its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 15.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 83,215 shares of the company's stock after selling 15,460 shares during the period. Eagle Asset Management Inc. owned about 0.28% of Disc Medicine worth $4,089,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of IRON. Amalgamated Bank grew its stake in Disc Medicine by 76.9% during the 2nd quarter. Amalgamated Bank now owns 568 shares of the company's stock valued at $26,000 after purchasing an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock worth $54,000 after buying an additional 337 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Disc Medicine by 19.5% in the third quarter. SG Americas Securities LLC now owns 4,864 shares of the company's stock worth $239,000 after buying an additional 793 shares during the last quarter. TD Asset Management Inc increased its stake in shares of Disc Medicine by 3.7% in the second quarter. TD Asset Management Inc now owns 40,732 shares of the company's stock worth $1,836,000 after buying an additional 1,468 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in Disc Medicine in the third quarter valued at $131,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IRON has been the subject of several research analyst reports. Morgan Stanley raised shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 target price for the company in a research report on Tuesday, November 5th. Jefferies Financial Group assumed coverage on Disc Medicine in a report on Wednesday, October 23rd. They issued a "buy" rating and a $89.00 price objective for the company. Wells Fargo & Company assumed coverage on Disc Medicine in a report on Thursday, August 22nd. They set an "overweight" rating and a $75.00 target price on the stock. HC Wainwright boosted their price target on Disc Medicine from $70.00 to $118.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Finally, Wedbush restated an "outperform" rating and set a $83.00 price objective (up from $75.00) on shares of Disc Medicine in a research note on Tuesday, November 12th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Disc Medicine currently has an average rating of "Buy" and an average price target of $85.80.

Disc Medicine Stock Down 0.7 %

IRON stock traded down $0.46 during mid-day trading on Monday, reaching $64.50. The company had a trading volume of 410,850 shares, compared to its average volume of 354,109. The stock's 50-day simple moving average is $52.44 and its two-hundred day simple moving average is $46.33. The stock has a market capitalization of $1.92 billion, a P/E ratio of -17.04 and a beta of 0.60. Disc Medicine, Inc. has a one year low of $25.60 and a one year high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.04) by $0.15. On average, research analysts forecast that Disc Medicine, Inc. will post -4.05 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider William Jacob Savage sold 9,158 shares of the company's stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $59.64, for a total value of $546,183.12. Following the completion of the sale, the insider now directly owns 40,405 shares of the company's stock, valued at approximately $2,409,754.20. This represents a 18.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William Richard White sold 7,136 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The disclosure for this sale can be found here. Insiders sold 16,696 shares of company stock valued at $984,058 in the last three months. 4.24% of the stock is currently owned by corporate insiders.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.